Nyhet

Retinoic Acids in Cancer Therapy

Mechanisms of Sensitivity, Resistance, and Methods of Delivery

AvSaeid Ghavami,Ali Zarrabi

Inbunden, Engelska, 2026

Del 23 i serien Cancer Sensitizing Agents for Chemotherapy

1 791 kr

Beställningsvara. Skickas inom 7-10 vardagar. Fri frakt över 249 kr.

Beskrivning

Retinoic Acids in Cancer Therapy: Mechanisms of Sensitivity, Resistance, and Methods of Delivery provides an overview of how All-Trans Retinoic Acid (ATRA) kills cancer cells and how some cells survive treatment. Focusing on the cellular pathways and compartments involved in ATRA-mediated inhibition of proliferation, this book also discusses how aggressive tumors develop escape routes conferring retinoic acid resistance.

Across 15 chapters, it describes the molecular structure and biological properties of ATRA, explains mechanisms of resistance, and defines ATRA’s efficacy in seven cancer types. It concludes with chapters on ATRA and cancer stem cell biology, strategies to improve treatment, future therapeutic perspectives, and delivery methods to reduce toxicity and enhance anticancer efficacy.

Each chapter includes Learning Objectives and a “What We Learn” section, making the book highly accessible for undergraduate, graduate trainees, scientists, physicians, and biotech companies. Adding simple, attractive schemes and informative tables makes it ideal for all interested in the current status of Retinoic Acids in Cancer Therapy. This book serves as a valuable resource for health professionals, scientists, researchers, clinical practitioners, and all those seeking to broaden their knowledge and develop new drugs or therapeutic strategies to improve ATRA’s efficacy in the treatment of resistant cancers.

Includes Learning Objectives and “What We Learn” sections in every chapter
Presents concise schematic figures illustrating apoptotic and autophagic pathways
Explains the interplay of apoptosis (intrinsic and extrinsic) and autophagy in ATRA-induced cell death
Discusses autophagy targeting to enhance ATRA effectiveness
Examines cancer stem cell fate modulation with ATRA
Highlights future directions and delivery strategies to minimize off-target effects

Produktinformation

Utgivningsdatum:2026-03-13
Mått:191 x 235 x undefined mm
Vikt:450 g
Format:Inbunden
Språk:Engelska
Serie:Cancer Sensitizing Agents for Chemotherapy
Antal sidor:408
Förlag:Elsevier Science
ISBN:9780443223051

Utforska kategorier

Onkologi inom Medicin
Farmakologi inom Medicin

Mer om författaren

Dr. Ghavami completed his undergraduate training MSc and PhD in clinical biochemistry. He is a cancer biologist and his research focusses on the importance of cross talk of three key cellular stress [apoptosis, autophagy and unfolded protein response (UPR)] in regulation of chemotherapy response in cancer cells including Glioblastoma, Rhabdomyosarcoma and non-small cell lung adenocarcinoma. Dr. Ghavami is currently honorary professor and co-founder of Autophagy Research Centre at Shiraz University of Medical Science and Tehran University of Medical Sciences, honorary professor at Katowice School of Technology, Poland. He is associate editor of BBA-Mol Basis of Disease, Molecular Neurobiology, BB Reports and IJMS. Ali Zarrabi is an associate professor and principal investigator in the Faculty of Engineering and Natural Sciences, Istinye University, Turkey. Trained as a chemical engineer (BSc and MSc) with a PhD in nanobiotechnology, he leads a research program at the interface of supramolecular chemistry, bioengineering, and nanomedicine to develop smart nano/biomaterials for simultaneous diagnosis and treatment of disease, with a particular focus on nanotheranostics, advanced wound dressings, skin patches, and translational nanomedicine.Marco Cordani obtained his Ph.D. at the University of Verona, working on the implication of mutated p53 proteins in metabolism and autophagy. Later, he has performed two postdoctoral stays, one at Universidad Autónoma de Madrid (2017) and another at the IMDEA Nanociencia (2018-2020), working on novel nanomedicine and gene editing strategies to counteract cancer. Currently, Postdoctoral Researcher at the University “Claude Bernard Lyon 1, characterizing the involvement of dependence receptors in cell death and metabolism.

Innehållsförteckning

1. Molecular structure and biological properties of all-trans retinoic acid2. Emerging frontiers in drug development of all-trans retinoic acid and its derivatives3. Cellular and molecular determinants of all trans retinoic acid sensitivity in different cancers4. Apoptosis, autophagy, and unfolded protein response and their impact on all-trans retinoic acid induced toxicity in cancer cells5. Mechanisms of resistance to all-trans retinoic acid and use of multi-target-directed ligand to fight against resistance6. Nanocarrier systems for targeted delivery of all-trans retinoic acid: design and mechanisms7. Advanced delivery systems for all-trans retinoic acid: challenges and opportunities in pharmacokinetics and bioavailability8. Mechanisms of sensitivity, resistance, and methods of delivery9. Efficiency of all-trans retinoic acid on gastric cancer10. All-trans retinoic acid and its role in glioblastoma therapy11. All-trans retinoic acid and vitamin A in neurodegeneration: from oncology to neuroprotection12. Efficiency of all-trans retinoic acid in liver cancer13. Efficiency of all-trans retinoic acid on colon cancer14. Retinoic acids in head and neck cancer therapy: mechanisms of sensitivity, resistance, and methods of delivery15. Role of artificial intelligence and machine learning in predicting all-trans retinoic acid treatment outcomes